95.59
Lemaitre Vascular Inc stock is traded at $95.59, with a volume of 349.10K.
It is down -1.95% in the last 24 hours and up +3.62% over the past month.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
See More
Previous Close:
$97.49
Open:
$98.55
24h Volume:
349.10K
Relative Volume:
1.16
Market Cap:
$2.18B
Revenue:
$256.28M
Net Income/Loss:
$62.40M
P/E Ratio:
35.22
EPS:
2.7139
Net Cash Flow:
$79.12M
1W Performance:
-5.94%
1M Performance:
+3.62%
6M Performance:
+13.50%
1Y Performance:
+18.35%
Lemaitre Vascular Inc Stock (LMAT) Company Profile
Name
Lemaitre Vascular Inc
Sector
Industry
Phone
781-221-2266
Address
63 SECOND AVENUE, BURLINGTON, MA
Compare LMAT vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
LMAT
Lemaitre Vascular Inc
|
95.59 | 2.18B | 256.28M | 62.40M | 79.12M | 2.7139 |
|
ISRG
Intuitive Surgical Inc
|
337.50 | 120.92B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
156.36 | 43.08B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
67.91 | 33.12B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
38.75 | 32.77B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
195.27 | 28.33B | 5.54B | 1.52B | 1.74B | 10.37 |
Lemaitre Vascular Inc Stock (LMAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-28-25 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Feb-28-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-13-25 | Initiated | Wells Fargo | Equal Weight |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Neutral |
| Aug-02-24 | Resumed | Lake Street | Buy |
| May-31-24 | Resumed | ROTH MKM | Buy |
| Apr-26-24 | Upgrade | Stifel | Hold → Buy |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Sector Weight |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-06-23 | Initiated | Oppenheimer | Outperform |
| Aug-03-23 | Downgrade | Jefferies | Buy → Hold |
| May-03-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-28-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-16-21 | Initiated | Jefferies | Buy |
| Feb-12-21 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Mar-16-20 | Upgrade | Sidoti | Neutral → Buy |
| Oct-24-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-24-19 | Upgrade | Lake Street | Hold → Buy |
| Oct-14-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jul-25-19 | Reiterated | Barrington Research | Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| Oct-08-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-08-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Jun-08-18 | Resumed | ROTH Capital | Buy |
| Apr-26-18 | Downgrade | Stifel | Buy → Hold |
| Apr-26-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Oct-27-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Oct-27-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-10-17 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-10-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-21-17 | Initiated | First Analysis Sec | Overweight |
| Feb-22-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-22-16 | Downgrade | Sidoti | Buy → Neutral |
| Jul-28-16 | Reiterated | Barrington Research | Outperform |
| Feb-25-16 | Reiterated | Barrington Research | Outperform |
View All
Lemaitre Vascular Inc Stock (LMAT) Latest News
LeMaitre Vascular, Inc. Revenue Breakdown – NASDAQ:LMAT - TradingView
LeMaitre Vascular Inc (LMAT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LMAT|LeMaitre Vascular Inc|Price:95.638|Chg%:-1.852 - TradingKey
LMAT|LeMaitre Vascular Inc|Price:98.390|Chg%:+0.900 - TradingKey
LMAT|LeMaitre Vascular Inc|Price:97.100|Chg%:-0.390 - TradingKey
First Trust Advisors LP Acquires 57,931 Shares of LeMaitre Vascular, Inc. $LMAT - MarketBeat
LeMaitre Vascular Inc (LMAT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Citizens reiterates LeMaitre Vascular stock rating on growth outlook By Investing.com - Investing.com Canada
LeMaitre Vascular (LMAT) Slips 1.36% as Stock Tests Key Support LevelsVolume Gap - dars.gov.et
Technical Reactions to LMAT Trends in Macro Strategies - Stock Traders Daily
Bessemer Group Inc. Boosts Position in LeMaitre Vascular, Inc. $LMAT - MarketBeat
Copeland Capital Management LLC Has $95.05 Million Stock Holdings in LeMaitre Vascular, Inc. $LMAT - MarketBeat
LMAT6268257 Bond Risk Profile - TradingView
LMAT6268257 Bond Coupon Profile — Rate & Payments - TradingView
LMAT6268257 Bond Profile — Key Metrics - TradingView
LeMaitre Vascular (NASDAQ:LMAT) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
LeMaitre Vascular to Report Second Quarter 2026 Financial Results on August 4 - Quiver Quantitative
LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026 - The Manila Times
LeMaitre Schedules Aug. 4 Call to Discuss Second-Quarter Results - Stock Titan
LeMaitre Vascular (NASDAQ:LMAT) Cut to "Hold" at Zacks Research - MarketBeat
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
LeMaitre Vascular Q1 2026 Earnings: EPS Slightly Beats Estimates, Stock RisesProduct Revenue Analysis - dars.gov.et
LeMaitre Vascular, Inc. $LMAT Shares Sold by Dividend Assets Capital LLC - MarketBeat
LeMaitre Vascular Inc. (LMAT) Q1 2026 Earnings: EPS Beats Estimates, Shares Climb 4%ROIC Trend Report - dars.gov.et
LeMaitre Vascular (NASDAQ:LMAT) Upgraded to "Buy" at Wall Street Zen - MarketBeat
LMAT Q1 2026 Earnings: Small EPS Beat Amid Steady PerformanceRevenue Inflection Point - dars.gov.et
LeMaitre Vascular (LMAT) Gains 4.2%: Key Technical Levels and Potential ScenariosWave Alternation - dars.gov.et
LeMaitre Vascular, Inc. $LMAT is Conestoga Capital Advisors LLC's 7th Largest Position - MarketBeat
LeMaitre Vascular, Inc. Financial Disclosures & Filings - TradingView
LMATLemaitre Vascular Inc Latest SEC Filings - Finviz
LeMaitre Vascular, Inc. $LMAT Shares Sold by SG Americas Securities LLC - MarketBeat
LMAT Technical Analysis & Stock Price Forecast - Intellectia AI
Trading the Move, Not the Narrative: (LMAT) Edition - Stock Traders Daily
Enterprise value to EBITDA forward of LeMaitre Vascular, Inc. – NASDAQ:LMAT - TradingView
Price to sales forward of LeMaitre Vascular, Inc. – NASDAQ:LMAT - TradingView
Price to book forward of LeMaitre Vascular, Inc. – NASDAQ:LMAT - TradingView
Enterprise value to EBIT forward of LeMaitre Vascular, Inc. – NASDAQ:LMAT - TradingView
LeMaitre Vascular, Inc. Actuals & Estimates (NASDAQ:LMAT) - TradingView
LeMaitre Vascular, Inc. Actuals & Estimates (SWB:LHU) - TradingView
LeMaitre Vascular Inc (LMAT) Institutional Confidence - TradingKey
LMAT Forecast — Price Target — Prediction for 2027 - TradingView
LeMaitre Vascular, Inc. Actuals & Estimates (TRADEGATE:LHU) - TradingView
LHU Forecast — Price Target — Prediction for 2027 - TradingView
Rockefeller Capital Management L.P. Sells 100,923 Shares of LeMaitre Vascular, Inc. $LMAT - MarketBeat
Riverbridge Partners LLC Buys Shares of 105,599 LeMaitre Vascular, Inc. $LMAT - MarketBeat
LeMaitre Vascular Inc. (NASDAQ:LMAT) Passes the Quality Test with Caviar Cruise Screen - ChartMill
LeMaitre Vascular Inc (LMAT) Valuation: PE, PB & Fair Value Analysis - TradingKey
LeMaitre Vascular Inc. (LMAT) Q1 2026 Earnings: EPS Beats Estimates, Stock Edges HigherEarnings Revision Upgrade - dars.gov.et
LeMaitre Vascular (NASDAQ:LMAT) Rating Lowered to Hold at Wall Street Zen - MarketBeat
LeMaitre Vascular Inc (LMAT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LeMaitre Vascular Inc (LMAT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lemaitre Vascular Inc Stock (LMAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):